Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Ex vivo gene editing in T cells and hematopoietic stem/progenitor cells (HSPCs) holds promise for treating diseases. Gene editing encompasses the delivery of a programmable editor RNA or ribonucleoprotein, often achieved ex vivo via electroporation, and when aiming for homology-driven correction of a DNA template, often provided by viral vectors together with a nuclease editor. Although HSPCs activate a robust p53-dependent DNA damage response upon nuclease-based editing, the responses triggered in T cells remain poorly characterized. Here, we performed comprehensive multiomics analyses and found that electroporation is the main culprit of cytotoxicity in T cells, causing death and cell cycle delay, perturbing metabolism, and inducing an inflammatory response. Nuclease RNA delivery using lipid nanoparticles (LNPs) nearly abolished cell death and ameliorated cell growth, improving tolerance to the procedure and yielding a higher number of edited cells compared with using electroporation. Transient transcriptomic changes upon LNP treatment were mostly caused by cellular loading with exogenous cholesterol, whose potentially detrimental impact could be overcome by limiting exposure. Notably, LNP-based HSPC editing dampened p53 pathway induction and supported higher clonogenic activity and similar or higher reconstitution by long-term repopulating HSPCs compared with electroporation, reaching comparable editing efficiencies. Overall, LNPs may allow efficient and harmless ex vivo gene editing in hematopoietic cells for the treatment of human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our work demonstrates the feasibility of using LNPs to deliver mRNA to T cells while maintaining viability and yield, aligning with findings from other studies in the field.24,32,36,85”
From Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles (2026) · cites this paper as [32]
In the citing paper
“However, the lower toxicity of LNP transfection offered significantly increased cell yield and could be advantageous during complex manufacturing workflows requiring multiple genetic modifications.24,32”
From Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles (2026) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences
Perez-Riverol, Y., Bai, J., Bandla, C., García-Seisdedos, D., Hewapathirana, S., Kamatchinathan, S., Kundu, D. J., Prakash, A., Frericks-Zipper, A., Eisenacher, M., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1038 · Cited by 6,125
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
On the Dependency of Cellular Protein Levels on mRNA Abundance
Liu, Y., Beyer, A., & Aebersold, R. (2016) · Cell · doi:10.1016/j.cell.2016.03.014 · Cited by 3,221
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment
Ma, X., Bi, E., Lu, Y., Su, P., Huang, C., Liu, L., Wang, Q., Yang, M., Kalady, M. F., Qian, J., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.04.002 · Cited by 1,033
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Research works printed but not linked: 43
- Naldini, 2019, Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives, EMBO Mol Med, 11, e9958, 10.15252/emmm.201809958 · DOI · Paper page
- Ferrari, 2021, Gene editing of hematopoietic stem cells: hopes and hurdles toward clinical translation, Front Genome Ed, 3, 618378, 10.3389/fgeed.2021.618378 · DOI
- June, 2018, Chimeric antigen receptor therapy, N Engl J Med, 379, 64, 10.1056/NEJMra1706169 · DOI · Paper page
- Lin, 2021, Advances in universal CAR-T cell therapy, Front Immunol, 12, 744823, 10.3389/fimmu.2021.744823 · DOI · Paper page
- Lidonnici, 2018, Gene therapy and gene editing strategies for hemoglobinopathies, Blood Cells Mol Dis, 70, 87, 10.1016/j.bcmd.2017.12.001 · DOI
- Pavel-Dinu, 2019, Gene correction for SCID-X1 in long-term hematopoietic stem cells, Nat Commun, 10, 1634, 10.1038/s41467-019-09614-y · DOI · Paper page
- Sweeney, 2017, Targeted repair of CYBB in X-CGD iPSCs requires retention of intronic sequences for expression and functional correction, Mol Ther, 25, 321, 10.1016/j.ymthe.2016.11.012 · DOI · Paper page
- Vavassori, 2021, Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome, EMBO Mol Med, 13, e13545, 10.15252/emmm.202013545 · DOI
- Kuo, 2018, Site-specific gene editing of human hematopoietic stem cells for X-linked hyper-IgM syndrome, Cell Rep, 23, 2606, 10.1016/j.celrep.2018.04.103 · DOI · Paper page
- Hubbard, 2016, Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome, Blood, 127, 2513, 10.1182/blood-2015-11-683235 · DOI · Paper page
- Lombardo, 2011, Site-specific integration and tailoring of cassette design for sustainable gene transfer, Nat Methods, 8, 861, 10.1038/nmeth.1674 · DOI · Paper page
- Ferrari, 2020, Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking, Nat Biotechnol, 38, 1298, 10.1038/s41587-020-0551-y · DOI · Paper page
- Batista Napotnik, 2012, Nanosecond electric pulses cause mitochondrial membrane permeabilization in Jurkat cells, Bioelectromagnetics, 33, 257, 10.1002/bem.20707 · DOI · Paper page
- Batista Napotnik, 2021, Cell death due to electroporation – a review, Bioelectrochemistry, 141, 107871, 10.1016/j.bioelechem.2021.107871 · DOI · Paper page
- Atsavapranee, 2021, Delivery technologies for T cell gene editing: applications in cancer immunotherapy, EBioMedicine, 67, 103354, 10.1016/j.ebiom.2021.103354 · DOI
- Gaudelli, 2020, Directed evolution of adenine base editors with increased activity and therapeutic application, Nat Biotechnol, 38, 892, 10.1038/s41587-020-0491-6 · DOI · Paper page
- Gattinoni, 2017, T memory stem cells in health and disease, Nat Med, 23, 18, 10.1038/nm.4241 · DOI · Paper page
- Danaei, 2018, Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems, Pharmaceutics, 10, 57, 10.3390/pharmaceutics10020057 · DOI · Paper page
- Perl, 2004, Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity, Trends Immunol, 25, 360, 10.1016/j.it.2004.05.001 · DOI · Paper page
- Bietz, 2017, Cholesterol metabolism in T cells, Front Immunol, 8, 1664, 10.3389/fimmu.2017.01664 · DOI
- Armstrong, 2010, ATP-binding cassette transporter G1 negatively regulates thymocyte and peripheral lymphocyte proliferation, J Immunol, 184, 173, 10.4049/jimmunol.0902372 · DOI · Paper page
- York, 2015, Limiting cholesterol biosynthetic flux spontaneously engages type I IFN signaling, Cell, 163, 1716, 10.1016/j.cell.2015.11.045 · DOI · Paper page
- Pavani, 2020, Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins, Nat Commun, 11, 3778, 10.1038/s41467-020-17552-3 · DOI · Paper page
- Pattabhi, 2019, In vivo outcome of homology-directed repair at the HBB gene in HSC using alternative donor template delivery methods, Mol Ther Nucleic Acids, 17, 277, 10.1016/j.omtn.2019.05.025 · DOI · Paper page
- Romero, 2019, Editing the sickle cell disease mutation in human hematopoietic stem cells: comparison of endonucleases and homologous donor templates, Mol Ther, 27, 1389, 10.1016/j.ymthe.2019.05.014 · DOI · Paper page
- Steinert, 2021, Mitochondrial metabolism regulation of T cell–mediated immunity, Annu Rev Immunol, 39, 395, 10.1146/annurev-immunol-101819-082015 · DOI
- Desdín-Micó, 2018, Mitochondrial activity in T cells, Mitochondrion, 41, 51, 10.1016/j.mito.2017.10.006 · DOI · Paper page
- Chyu, 2014, Cholesterol lowering modulates T cell function in vivo and in vitro, PLoS One, 9, e92095, 10.1371/journal.pone.0092095 · DOI
- Surls, 2012, Increased membrane cholesterol in lymphocytes diverts T-cells toward an inflammatory response, PLoS One, 7, e38733, 10.1371/journal.pone.0038733 · DOI
- Gao, 2014, Regulation of high-density lipoprotein on hematopoietic stem/progenitor cells in atherosclerosis requires scavenger receptor type BI expression, Arterioscler Thromb Vasc Biol, 34, 1900, 10.1161/ATVBAHA.114.304006 · DOI
- Yvan-Charvet, 2010, ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation, Science, 328, 1689, 10.1126/science.1189731 · DOI · Paper page
- Westerterp, 2012, Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways, Cell Stem Cell, 11, 195, 10.1016/j.stem.2012.04.024 · DOI · Paper page
- Ghassemi, 2022, Rapid manufacturing of non-activated potent CAR T cells, Nat Biomed Eng, 6, 118, 10.1038/s41551-021-00842-6 · DOI · Paper page
- Ghassemi, 2020, Enhancing chimeric antigen receptor T cell anti-tumor function through advanced media design, Mol Ther Methods Clin Dev, 18, 595, 10.1016/j.omtm.2020.07.008 · DOI · Paper page
- Xu, 2020, Challenges and clinical strategies of CAR T-cell therapy for acute lymphoblastic leukemia: overview and developments, Front Immunol, 11, 569117, 10.3389/fimmu.2020.569117 · DOI
- Honaker, 2020, Gene editing to induce FOXP3 expression in human CD4+ T cells leads to a stable regulatory phenotype and function, Sci Transl Med, 12, 6422, 10.1126/scitranslmed.aay6422 · DOI
- Goodwin, 2020, CRISPR-based gene editing enables FOXP3 gene repair in IPEX patient cells, Sci Adv, 6, eaaz0571, 10.1126/sciadv.aaz0571 · DOI · Paper page
- Fox, 2022, Therapeutic gene editing of T cells to correct CTLA-4 insufficiency, Sci Transl Med, 14, eabn5811, 10.1126/scitranslmed.abn5811 · DOI
- Goldman, 2008, Characterization of primitive hematopoietic cells from patients with dyskeratosis congenita, Blood, 111, 4523, 10.1182/blood-2007-10-120204 · DOI · Paper page
- Croop, 2001, Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia, Blood, 98, 2917, 10.1182/blood.V98.10.2917 · DOI · Paper page
- Six, 2020, Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs, Blood, 135, 1219, 10.1182/blood.2019002350 · DOI · Paper page
- Omer-Javed, 2022, Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells, Cell, 185, 2248, 10.1016/j.cell.2022.04.039 · DOI
- Samuelson, 2021, Multiplex CRISPR/Cas9 genome editing in hematopoietic stem cells for fetal hemoglobin reinduction generates chromosomal translocations, Mol Ther Methods Clin Dev, 23, 507, 10.1016/j.omtm.2021.10.008 · DOI
Cited by
Castiello, M. C., Brandas, C., Ferrari, S., Porcellini, S., Sacchetti, N., Canarutto, D., Draghici, E., Merelli, I., Barcella, M., Pelosi, G., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adh8162 · Cited by 25
Self-citationHuman T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles
Ramamurthy, A., Scimonelli, G., Murphy, W. L., & Saha, K. (2026) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2026.103081
Metadata
- Authors
- Vavassori, V., Ferrari, S., Beretta, S., Asperti, C., Albano, L., Annoni, A., Gaddoni, C., Varesi, A., Soldi, M., Cuomo, A., Bonaldi, T., Radrizzani, M., Merelli, I., & Naldini, L.
- Affiliations
- 1San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
- 3Department of Molecular Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2023-08-31
- Volume
- 142
- Issue
- 9
- Pages
- 812-826
- ISSN
- 0006-4971
- 1528-0020
- Cited by
- 100
- References
- 18
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells. https://app.cochat.ai/papers/10.1182/blood.2022019333
- The paper
- Vavassori, V., Ferrari, S., Beretta, S., Asperti, C., Albano, L., Annoni, A., Gaddoni, C., Varesi, A., Soldi, M., Cuomo, A., Bonaldi, T., Radrizzani, M., Merelli, I., & Naldini, L. (2023). Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells. Blood. https://doi.org/10.1182/blood.2022019333
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.